Website profile

Indian Pharma Post

Ajanta Pharma to hold 47th annual general meeting on July 16 Indian Pharma Post Get the latest News & Research on Pharma industry, Viewpoints, Events, Videos, statistics, indianpharmapost.com

  • 190articles · 30d
  • 8+ hour agolatest article
  • Aug 17, 2026earliest in window
  • 89%with images
  • 244avg words
articles per day
Categories
  • Medical 137
  • Health & Wellness 101
  • Economy, Business & Finance 83
  • Health 74
  • Business & Industrial 68
  • Finance & Business 35
  • Science & Technology 21
  • News 14
Bylines

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

@pharma_indian
indianpharmapost.com > startup > c-camp-national-bio-entrepreneurship-competition-2026-recognises-15-startups-and-four-student-teams-21825

C-CAMP National Bio Entrepreneurship competition 2026 recognises 15 startups and four student teams

9+ hour, 12+ min ago   (509+ words) The winners were announced at the finale held in Bengaluru, in the presence of Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited Fifteen startups and four student teams have emerged as winners of the ninth edition of the C-CAMP National Bio Entrepreneurship…...

@pharma_indian
indianpharmapost.com > biopharma > biocon-inks-10-year-deal-to-supply-breast-cancer-therapy-to-brazil-21757

Biocon inks 10-year deal to supply breast cancer therapy to Brazil

5+ day, 20+ hour ago   (256+ words) Biocon Limited has signed a landmark partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil. This collaboration marks a significant step forward in scaling the production and commercialization of this HER2-positive breast cancer therapy under the country's Productive Development…...

@pharma_indian
indianpharmapost.com > news > alkem-launches-indias-first-patented-ginsenoside-exosome-hair-growth-serum-renocia-exo-21761

Alkem launches India’s first patented Ginsenoside Exosome hair growth Serum, Renocia Exo

5+ day, 20+ hour ago   (169+ words) Renocia Exo offers a new multitargeted approach to hair loss management by supporting the biology of the hair follicle-not just hair growth Alkem Laboratories has launched Renocia Exo, a next-generation hair regeneration therapy designed to scientifically support and vitalise hair…...

Google News
indianpharmapost.com > medical-device > medtronic-to-invest-700-million-in-hong-kong-surgical-robotics-firm-21667

Medtronic to invest $700 million in Hong Kong surgical robotics firm

1+ week, 5+ day ago   (264+ words) Medtronic has agreed to make an approximately US$700 million strategic investment in Cornerstone Robotics, a Hong Kong-based surgical robotics company, under a partnership aimed at expanding access to robotic-assisted surgery globally. As part of the agreement, Medtronic will also secure…...

@pharma_indian
indianpharmapost.com > biopharma > amyl-therapeutics-raises-825m-to-advance-pan-amyloid-therapy-towards-clinical-development-21657

Amyl Therapeutics raises €8.25M to advance pan-amyloid therapy towards clinical development

1+ week, 6+ day ago   (284+ words) Belgian biotech to complete preclinical development, prepare lead candidate for GMP manufacturing and double its R&D team The financing was split equally between public grants and private investment, with participation from new family offices and business angels, as well…...

@pharma_indian
indianpharmapost.com > interviews > we-recently-launched-aminosaaya-system-in-india-dr-purushottam-sutar-product-business-development-manager-south-asia-hitachi-high-tech-india-72

We recently launched AminoSAAYA System in India: Dr. Purushottam Sutar, Product & Business Development Manager - South Asia, Hitachi High-Tech India

1+ week, 6+ day ago   (55+ words) Dr. Rajesh Nair appointed CEO of Park Group of Hospitals India cuts malaria cases and deaths by nearly 80% over a decade IPC launches 12 reference standards to strengthen quality of phytopharma Cipla’s InvaGen plant in New York gets VAI status from…...

@pharma_indian
indianpharmapost.com > news > thermo-fisher-unveils-empad-g2-detector-to-advance-4d-stem-materials-research-21648

Thermo Fisher unveils EMPAD G2 detector to advance 4D STEM materials research

2+ week, 1+ hour ago   (55+ words) Dr. Rajesh Nair appointed CEO of Park Group of Hospitals India cuts malaria cases and deaths by nearly 80% over a decade IPC launches 12 reference standards to strengthen quality of phytopharma Cipla’s InvaGen plant in New York gets VAI status from…...

Google News
indianpharmapost.com > biopharma > cipla-inks-exclusive-licence-deal-with-sino-biopharma-for-her2-targeted-adc-21651

Cipla inks exclusive licence deal with Sino Biopharma for HER2-targeted ADC

2+ week, 24+ min ago   (341+ words) Partnership gives Cipla development and commercialisation rights for TQB2102 across India, South Africa and five other emerging markets Under the agreement, SBP Group subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ) has granted Cipla exclusive rights to develop and commercialise…...

@pharma_indian
indianpharmapost.com > people > glenmark-pharma-appoints-avneesh-mishra-as-dgm-corporate-quality-internal-audit-compliance-21632

Glenmark Pharma appoints Avneesh Mishra as DGM – Corporate Quality Internal Audit & Compliance

2+ week, 6+ hour ago   (119+ words) Mishra brings extensive experience across quality assurance, GMP compliance, internal audits and pharmaceutical quality management systems. Prior to joining Glenmark, he served as AGM – Lead, Global Internal Audit (GMP) at Dr. Reddy's Laboratories. Over the course of his career, Mishra…...

@pharma_indian
indianpharmapost.com > clinical-trials > haemalogix-treats-first-patient-with-kmcar-t-cell-therapy-in-phase-i-multiple-myeloma-trial-21634

HaemaLogiX treats first patient with KMCAR T-cell therapy in Phase I multiple myeloma trial

2+ week, 7+ hour ago   (480+ words) The Australian biotech player is evaluating the therapy in patients with relapsed or refractory kappa-restricted multiple myeloma HaemaLogiX, biotech company based in Australia, has treated the first patient with its investigational KMCAR T-cell therapy in a Phase I clinical trial…...